Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence

Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn.

Original languageEnglish
Pages (from-to)757-759
Number of pages3
JournalIndian Heart Journal
Volume73
Issue number6
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • ACE2
  • Adrenergic
  • Beta-blocker
  • COVID-19
  • Hypertension

Fingerprint

Dive into the research topics of 'Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence'. Together they form a unique fingerprint.

Cite this